
BiomX raises $32M series B to bring first two therapies to clinic
Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday, 20th February, that will take its lead candidate, acne therapy BX001,...
Search
All
Phage therapy company BiomX Ltd. (Ness Ziona, Israel) raised a $32 million series B round on Wednesday, 20th February, that will take its lead candidate, acne therapy BX001,...
Seventure Keeps up Pace of Its International Microbiome Investments, Closing Four Deals Spanning Seed to Series C
Vedanta Bioscience, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human...
The latest investment will help drive expansion and accelerate research & development to introduce new and novel ingredients to the market.
The $30 million in new investment will fuel expansion and accelerate R&D project execution. This funding round opens up an opportunity to explore different ways to meet...
A-Mansia Biotech, a microbiome company, has announced the appointment of Cees de Jong as the Chairman of its Board of Directors. His experience of successfully managing several...
It's a decisive step in BALYO’s development that supports the added value of BALYO’s robotic solutions and will potentially boost their deployment. AMAZON would obtain the...
Talentsoft, the European leader in learning and human capital management software, today announced that it has closed a funding round of $50 million. Francisco Partners leads...
Specialized in smart medical devices, FeetMe focused on the development of portable insoles that measure progression in patients with multiple sclerosis (MS).
Israeli microbiome company BiomX, which is developing customized phage therapies, has announced that it has entered into a collaboration with Janssen the therapy R&D arm of...